Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA.
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7431-6. doi: 10.1073/pnas.1002301107. Epub 2010 Mar 15.
Hepatitis C virus (HCV), a member of the Flaviviridae family, is a single-stranded positive-sense RNA virus that infects >170 million people worldwide and causes acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Despite its ability to block the innate host response in infected hepatocyte cell lines in vitro, HCV induces a strong type 1 interferon (IFN) response in the infected liver. The source of IFN in vivo and how it is induced are currently undefined. Here we report that HCV-infected cells trigger a robust IFN response in plasmacytoid dendritic cells (pDCs) by a mechanism that requires active viral replication, direct cell-cell contact, and Toll-like receptor 7 signaling, and we show that the activated pDC supernatant inhibits HCV infection in an IFN receptor-dependent manner. Importantly, the same events are triggered by HCV subgenomic replicon cells but not by free virus particles, suggesting the existence of a novel cell-cell RNA transfer process whereby HCV-infected cells can activate pDCs to produce IFN without infecting them. These results may explain how HCV induces IFN production in the liver, and they reveal a heretofore unsuspected aspect of the innate host response to viruses that can subvert the classical sensing machinery in the cells they infect, and do not infect or directly activate pDCs.
丙型肝炎病毒(HCV)属于黄病毒科,是一种单链正链 RNA 病毒,感染全球超过 1.7 亿人,导致急性和慢性肝炎、肝硬化和肝细胞癌。尽管 HCV 能够在体外感染的肝细胞系中阻断固有宿主反应,但它在感染的肝脏中诱导强烈的 I 型干扰素(IFN)反应。体内 IFN 的来源及其诱导方式目前尚不清楚。在这里,我们报告 HCV 感染的细胞通过一种需要活跃病毒复制、直接细胞-细胞接触和 Toll 样受体 7 信号的机制,在浆细胞样树突状细胞(pDC)中触发强烈的 IFN 反应,我们还表明激活的 pDC 上清液以 IFN 受体依赖性方式抑制 HCV 感染。重要的是,相同的事件由 HCV 亚基因组复制子细胞触发,但不由游离病毒颗粒触发,这表明存在一种新的细胞间 RNA 转移过程,通过该过程,HCV 感染的细胞可以激活 pDC 产生 IFN,而不感染它们。这些结果可能解释了 HCV 如何在肝脏中诱导 IFN 产生,并且它们揭示了固有宿主对病毒反应的一个迄今为止尚未被怀疑的方面,该方面可以颠覆其感染的细胞中的经典感应机制,并且不感染或直接激活 pDC。
Proc Natl Acad Sci U S A. 2010-3-15
Health Sci Rep. 2024-11-18
Bioact Mater. 2022-9-22
Int J Mol Sci. 2022-6-30
Nature. 2007-10-18
Virol J. 2006-10-28